See more : CPT Drives and Power Public Company Limited (CPT.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Corvus Pharmaceuticals, Inc. (CRVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corvus Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Arigatou Services Company, Limited (3177.T) Income Statement Analysis – Financial Results
- NexGen Energy Ltd. (NXG.AX) Income Statement Analysis – Financial Results
- FY Group Ltd. (6807.TW) Income Statement Analysis – Financial Results
- K9 Gold Corp. (WDFCF) Income Statement Analysis – Financial Results
- PT Bumi Citra Permai Tbk (BCIP.JK) Income Statement Analysis – Financial Results
Corvus Pharmaceuticals, Inc. (CRVS)
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 151.00K | 367.00K | 460.00K | 632.00K | 743.00K | 847.00K | 842.00K | 594.00K | 148.00K | 0.00 |
| Gross Profit | -151.00K | -367.00K | -460.00K | -632.00K | -743.00K | -847.00K | -842.00K | -594.00K | -148.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.53M | 24.47M | 29.12M | 31.83M | 37.98M | 38.59M | 46.31M | 29.36M | 11.35M | 41.46K |
| General & Administrative | 6.88M | 8.10M | 9.52M | 11.93M | 10.88M | 10.64M | 10.22M | 7.62M | 2.42M | 134.18K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.88M | 8.10M | 9.52M | 11.93M | 10.88M | 10.64M | 10.22M | 7.62M | 2.42M | 134.18K |
| Other Expenses | 0.00 | 587.00K | 235.00K | 37.46M | 0.00 | 0.00 | 0.00 | 0.00 | -17.60M | 0.00 |
| Operating Expenses | 23.41M | 32.57M | 38.63M | 43.76M | 48.85M | 49.22M | 56.52M | 36.98M | 13.77M | 175.64K |
| Cost & Expenses | 23.41M | 32.57M | 38.63M | 43.76M | 48.85M | 49.22M | 56.52M | 36.98M | 13.77M | 175.64K |
| Interest Income | 0.00 | 654.00 | 0.00 | 540.00K | 2.18M | 2.28M | 861.00K | 601.00K | 35.00K | 0.00 |
| Interest Expense | 1.58M | 654.00K | 15.00K | 540.00K | 2.18M | 2.28M | 0.00 | 601.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 151.00K | 367.00K | 460.00K | 632.00K | 743.00K | 847.00K | 842.00K | 594.00K | 148.00K | 175.64K |
| EBITDA | -26.88M | -40.94M | -42.78M | -5.36M | -48.85M | -46.09M | -54.82M | -35.78M | -31.19M | 14.64K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -23.41M | -32.57M | -38.63M | -43.76M | -48.85M | -49.22M | -56.52M | -36.98M | -13.77M | -175.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -3.62M | -8.74M | -4.61M | 37.77M | 2.18M | 2.28M | 861.00K | 601.00K | -17.57M | 0.00 |
| Income Before Tax | -27.03M | -41.31M | -43.24M | -6.00M | -46.67M | -46.94M | -55.66M | -36.38M | -31.34M | -175.64K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 8.74M | -5.04M | -1.17M | -2.93M | 2.28M | -842.00K | -594.00K | -35.00K | 0.00 |
| Net Income | -27.03M | -50.05M | -38.20M | -4.82M | -43.75M | -46.94M | -55.66M | -36.38M | -31.34M | -175.64K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
| EPS Diluted | -0.56 | -1.08 | -0.91 | -0.16 | -1.49 | -1.71 | -2.72 | -2.36 | -1.54 | -1.03 |
| Weighted Avg Shares Out | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 20.41M | 170.00K |
| Weighted Avg Shares Out (Dil) | 48.03M | 46.55M | 41.85M | 29.48M | 29.35M | 27.51M | 20.49M | 15.42M | 20.41M | 170.28K |
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Corvus Pharmaceuticals Eyes Phase 3 Trials: Soquelitinib's Promise In PTCL
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
Corvus Pharmaceuticals Is Ready To Take Flight
The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2024 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports